Patricia Ducray-Sanwald
Grenzacher Street 124
Basel, BS, Switzerland
Basel, BS, Switzerland
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Integrating population heterogeneity in drug research and early development: a proactive strategy.
Journal: Drug discovery today
Published: April 13, 2026
Quantitative relationship between tominersen concentrations in cerebrospinal fluid and biomarker changes in Huntington's disease patients.
Journal: British journal of clinical pharmacology
Published: June 10, 2025
NfL concentration in CSF is a quantitative marker of the rate of neurodegeneration in aging and Huntington's disease: a semi-mechanistic model-based analysis.
Journal: Frontiers in neuroscience
Published: April 19, 2024
Tominersen in Adults with Manifest Huntington's Disease.
Journal: The New England journal of medicine
Published: December 06, 2023
Development of a population pharmacokinetic model to characterize the pharmacokinetics of intrathecally administered tominersen in cerebrospinal fluid and plasma.
Journal: CPT: pharmacometrics & systems pharmacology
Published: January 02, 2023
Randomized, Double-Blind, Placebo-Controlled Trial of the mGlu2/3 Negative Allosteric Modulator Decoglurant in Partially Refractory Major Depressive Disorder.
Journal: The Journal of clinical psychiatry
Published: July 17, 2018
Mathematical Disease Progression Modeling in Type 2/3 Spinal Muscular Atrophy.
Journal: Muscle & nerve
Published: November 10, 2017
The effect of aleglitazar on the pharmacokinetics and pharmacodynamics of S- and R-warfarin in healthy male subjects.
Journal: Journal of cardiovascular pharmacology
Published: October 26, 2013
Showing 1-9 of 9
Last Updated: 09/26/2026